Key clinical point:
Major finding: Median progression-free survival was 5.6 months with tivozanib and 3.9 months with sorafenib (hazard ratio, 0.73; P = .0165).
Study details: A phase 3 open-label, randomized controlled trial among 350 patients with treatment-refractory advanced RCC (TIVO-3 trial).
Disclosures: Dr. Rini reported that he has a consulting role with Aveo, which sponsored the trial, and financial relationships with several other companies.
Rini BI et al. GUCS 2019,.